Achillion Pharmaceuticals
ACHILLION PHARMACEUTICALS INC (Form: SC 13G/A, Received: 02/14/2017 17:59:49)

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

(Amendment No. 4)*

 

ACHILLION PHARMACEUTICALS, INC.
(Name of Issuer)

 

Common Stock, $0.001 par value per share
(Title of Class of Securities)

 

00448Q201
(CUSIP Number)

 

December 31, 2016
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ¨ Rule 13d-1(b)
  x Rule 13d-1(c)
  ¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 00448Q201 13G

 

  1.

Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

RA Capital Healthcare Fund, L.P.

 

  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ¨
    (b) ¨
 
  3. SEC Use Only
 
  4. Citizenship or Place of Organization           Delaware
 
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power                          0 shares
 
6. Shared Voting Power                     0 shares
 
7. Sole Dispositive Power                  0 shares
 
8. Shared Dispositive Power              0 shares
 
  9.

Aggregate Amount Beneficially Owned by Each Reporting Person

0 shares

 
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)            ¨
 
  11.

Percent of Class Represented by Amount in Row (9)

0.0%

 
  12.

Type of Reporting Person (See Instructions)

PN (Limited Partnership)

 

 

 

 

 

CUSIP No. 00448Q201 13G

 

Item 1.

 

(a)           Name of Issuer: Achillion Pharmaceuticals, Inc. (the “Issuer”).

 

(b)           Address of the Issuer’s Principal Executive Offices: 300 George Street, New Haven, CT 06511.

 

Item 2.

 

(a)           Name of Person Filing: This statement on Schedule 13G is being filed by and RA Capital Healthcare Fund, L.P. (the “Fund”). The Fund is referred to herein as the “Reporting Person.”

 

(b)           Address of Principal Business Office: The principal business office of the Reporting Persons is c/o RA Capital Management, LLC, 20 Park Plaza, Suite 1200, Boston, MA 02116.

 

(c)           Citizenship: The Fund is a Delaware limited partnership.

 

(d)           Title and Class of Securities: Common stock (“Common Stock”)

 

(e)           CUSIP Number: 00448Q201

 

Item 3.           If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable.

 

Item 4.           Ownership:

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a)

Amount Beneficially Owned:

See the response(s) to Item 9 on the attached cover page(s).

   
(b)

Percent of Class:

See the response(s) to Item 11 on the attached cover page(s).

   
(c) Number of shares as to which such person has:
   
  (i)

sole power to vote or to direct the vote:

See the response(s) to Item 5 on the attached cover page(s).

 

 

 

 

CUSIP No. 00448Q201 13G

 

  (ii)

shared power to vote or to direct the vote

See the response(s) to Item 6 on the attached cover page(s).

     
  (iii)

sole power to dispose or to direct the disposition of

See the response(s) to Item 7 on the attached cover page(s).

     
  (iv)

shared power to dispose or to direct the disposition of

See the response(s) to Item 8 on the attached cover page(s).

 

Item 5.           Ownership of Five Percent or Less of a Class:

 

If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .

 

Item 6.            Ownership of More than Five Percent on Behalf of Another Person:

 

Not applicable.

 

Item 7.            Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

 

Not applicable.

 

Item 8.           Identification and Classification of Members of the Group:

 

Not applicable.

 

Item 9.           Notice of Dissolution of Group:

 

Not applicable.

 

Item 10.         Certification:

 

By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  Date: F ebruary 14 , 2017
   
  RA CAPITAL HEALTHCARE FUND, L.P.
   
  By: RA Capital Management, LLC
  Its: General Partner
   
  By: /s/ Rajeev Shah
  Rajeev Shah
  Authorized Signatory